Analyst Bill Sutherland of Benchmark Co. maintained a Buy rating on Quipt Home Medical, with a price target of $4.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bill Sutherland has given his Buy rating due to a combination of factors including Quipt Home Medical’s recent announcement of a definitive agreement to be acquired by Kingswood Capital Management and Forager Capital Management. This acquisition deal, valued at $260 million and priced at $3.65 per share, is an all-cash transaction that provides a premium to current shareholders and is expected to close in the first half of 2026, pending necessary approvals.
Additionally, Quipt’s financial performance has exceeded expectations, with a notable increase in revenue and adjusted EBITDA for the fiscal year 2025. The company reported an 11.4% year-over-year revenue growth and a 17% quarter-over-quarter increase, surpassing the anticipated $60 million model. This was driven by both organic growth and the successful integration of recent acquisitions, Ballad Health and Hart Medical. These positive financial results, coupled with the strategic acquisition agreement, underpin Sutherland’s positive outlook on Quipt Home Medical’s stock.